行情

HRTX

HRTX

Heron Inc
NASDAQ

实时行情|Nasdaq Last Sale

21.58
+0.74
+3.55%
盘后: 21.76 +0.18 +0.83% 17:57 11/15 EST
开盘
21.05
昨收
20.84
最高
21.67
最低
20.77
成交量
117.96万
成交额
--
52周最高
29.49
52周最低
15.68
市值
19.07亿
市盈率(TTM)
-8.6688
分时
5日
1月
3月
1年
5年

分析师评级

10位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

HRTX 新闻

  • Heron Therapeutics: Looking Solid Heading Into 2020
  • Seeking Alpha - Article.2天前
  • Heron Therapeutics (HRTX) Upgraded to Buy: Here's Why
  • Zacks.2天前
  • Heron Therapeutics, Inc. Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
  • Simply Wall St..2天前
  • Heron Therapeutics to Present at the Stifel 2019 Healthcare Conference
  • PR Newswire.4天前

更多

所属板块

生物技术和医学研究
+1.25%
制药与医学研究
+1.34%

热门股票

名称
价格
涨跌幅

HRTX 简况

Heron Therapeutics, Inc. is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company's product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology. The Company's SUSTOL (granisetron) injection, extended release is being developed for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC). HTX-019, which is an intravenous formulation of aprepitant, a neurokinin-1 (NK1) receptor antagonist, is being developed for the prevention of CINV. HTX-011, a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam, is being developed for the prevention of post-operative pain. HTX-011 is in Phase II clinical trials.
展开

Webull提供Heron Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。